Effect of zolmitriptan on blood pressure-relevant cardiovascular biomarkers in rats with experimentally induced hypertension

Rojgar Hamed Ali

doi:10.15218/zjms.2023.006

Authors

Rojgar Hamed Ali Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2023.006

Keywords:

Zolmitriptan, Blood pressure, Hypertension, Nitric oxide, Endothelin-1

Abstract

Background and objective: Zolmitriptan is among widely used medicines for the management of migraine attach, zolmitriptan is acting through stimulating serotonin (5-HT1B/1D) receptors that will cause cranial vasoconstriction. This study was aimed to compare and evaluate the impact of zolmitriptan on the relevant cardiovascular and renal biomarkers during hypertension in rats with experimentally induced hypertension.

Methods: Twenty-four Wister albino male rats were randomly divided into four groups of six rats each. The first group (Group I) of rats served as the control group. To induce hypertension, the rats in the second (Group II), third (Group III) and fourth (Group IV) groups have received an intraperitoneal injection of cadmium chloride CdCl2 a dose of 1.5 mg/kg/day for 14 days. The rats in Group II were considered as the positive control. Whereas, rats in Group III received zolmitriptan orally (2 mg/kg/day), and Group IV rats received nifedipine dose of 10mg/kg for two weeks concurrently with CdCl₂.

Results: Inducing hypertension with CdCl2 injection significantly increased the systolic, diastolic, and mean blood pressure in Group II compared with Group I, respectively. The systolic, diastolic, and mean blood pressure in rats that received zolmitriptan did not exhibit any statistically significant differences from the rats in Group II, whereas nifedipine has significantly reduced blood pressure in group IV rats.

Intraperitoneal injection of CdCl₂ increased the concentrations of endothelin and nitric oxide as well as renin activity level in hypertensive Group II rats compared to control rats. Zolmitriptan administration did not produce any significant change in the endothelin and nitric oxide levels.

Inducing hypertension in rats significantly reduced the corticosterone level. In contrast, administering medications in Group III and VI rats did not produce any statistically significant change in the serum concentration of corticosterone.

Conclusion: Zolmitriptan administration (2 mg/kg/day, p.o) showed no statistically significant effects on the systolic, diastolic, and mean blood pressure in rats with experimentally induced hypertension. Zolmitriptan has also failed to produce any statistically significant change in the levels of endothelin-1, renin, nitric oxide, corticosterone, and serum creatinine in rats with hypertension.

Metrics

Metrics Loading ...

References

Courault P, Demarquay G, Zimmer L, Lancelot S. Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives. Fundam Clin Pharmacol. 2021; 35(3):595–619. https://doi.org/10.1111/fcp.12636.

Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002; 59(7):1084–8. DOI:10.1001/archneur.59.7.1084.

Leroux E, Buchanan A, Lombard L, Loo LS, Bridge D, Rousseau B, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020; 37(12):4765–96. DOI: 10.1007/s12325-020-01494-9 .

Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine?. Pain 2005; 115(1-2):1. DOI: 10.1016/j.pain.2005.03.008.

Yegdaneh A, Mobasherian M. The effect of 5. Sargassum angustifolium ethanol extract on cadmium chloride-induced hypertension in rat. J Pharm Pharmacogn. 2021; 8(1):81–9. DOI: 10.22127/RJP.2020.255203.1637.

Maurya V, Kumar P, Chakraborti S, Singh AK, Bhadauria AS, Kumar U, et al. Zolmitriptan attenuates hepatocellular carcinoma via activation of caspase mediated apoptosis. Chem Biol Interact. 2019; 308:120–9. DOI: 10.1016/j.cbi.2019.05.033

Kumar BS, Rajanna A, Balakrishna N. Combined anticonvulsant effect of nifedipine and pentazocine in experimentally induced seizures by maximal electro shock method in mice. J Drug Deliv Ther. 2019; 9(4):288–91. DOI:10.18203/2319-2003.ijbcp20193194.

Dizaye K, Ali RH. Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure. BMC Pharmacol. 2019; 20(1):1–7. DOI:10.1186/s40360-019-0304-z.

Gao L, Li X. Protective Effect of Tubotaiwine on Cadmium-Induced Hypertension in Rats through Reduction in Arterial Stiffness and Vascular Remodeling. Dokl. 2021; 500(1):368–75. Pleiades Publishing. DOI: 10.1134/S1607672921050136.

Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs. 1999; 58(2):347–74. DOI: 10.2165/00003495-199958020-00016.

Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, et al. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci. 2018; 19(9):2605. DOI: 10.1093/cvr/cvq248.

Jonak C, Nakagami H, Hirt H. Heavy metal stress. Activation of distinct mitogen-activated protein kinase pathways by copper and cadmium. Plant Physiol. 2004; 136(2):3276–83. DOI:10.1104/pp.104.045724.

Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med. 2002; 112(2):135–40. DOI: https://doi.org/10.1016/S0002-9343(01)01064-6.

Tullo V, Bussone G, Omboni S, Barbanti P, Cortelli P, Curone M, et al. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies. Neurol Sci. 2013; 34(1):87–91. DOI: 10.1007/s10072-013-1367-z.